Cortés AA, Sánchez DG, Rivera LMR, Aranda OJR, Robles RRJ, Benítez AG

Language: Spanish
References: 11
Page: 15-21
PDF size: 156.94 Kb.

ABSTRACT

Among the diseases transmitted by transfusion in Mexico, 5 are mandatory for screening and detection for health risks and the costs they cause: HCV, HBV, syphilis, Chagas and HIV type 1 and 2. Within these TTD (transfusion-transmitted diseases) hepatitis defined as inflammation of liver cells, caused in most cases by viruses is the central issue in this article, three cases detected by technology of nucleic acids are exposed. One of them achieving detailed follow-up from the reactivity to NAT, seroconversion to acute stage and diagnosis by means of viral panel. The other two cases detected in the window period when donating, with subsequent seroconversion evidenced after viral panel control in laboratories of the Specialty Medical Unit of High Specialty Hospital CMNSXXI. Evidence that the implementation of nucleic acid detection technology in blood banks increases transfusion safety, by significantly reducing the residual risk of transfusing blood components found in said window period, avoiding the consequent impact on the health of people who may have been transfused with these blood components and donors when the infection was detected early.

REFERENCES

1. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. J Transl Med. 2007; 5: 25.

2. Rojo MJ. Enfermedades infecciosas transmitidas por transfusión. Panorama internacional y en México. Gac Med Mex. 2014; 150 (1): 78-83.

3. World Health Organization. Universal access to safe blood transfusion [Internet]. 2008. Disponible en: https://www.who.int/bloodsafety/publications/UniversalAccesstoSafeBT.pdf?ua=1

4. Norma Oficial Mexicana NOM-SSA1-253-2012 “Para la disposición de sangre humana y sus componentes con fines terapéuticos” [Internet]. 2012. Disponible en: http://www.cnts.salud.gob.mx/descargas/NOM-253-SSA1-2012.pdf

5. Panduro A, Escobedo-Meléndez G, Fierro NA, Ruiz Madrigal B, Zepeda-Carrillo EA, Román S. Epidemiología de las hepatitis virales en México. Salud Pública Méx. 2011; 53: S37-S45. Disponible en: http://saludpublica.mx/index.php/spm/article/view/5023/10010

6. Benítez Arvizu G. Detección de un periodo de ventana de hepatitis B. Periodo de ventana en la medicina transfusional, importancia de la tecnología NAT para la seguridad transfusional. Simposio organizado por Grifols en el Congreso de la Asociación Mexicana de Medicina Transfusional. 21 de septiembre de 2017. pp. 22-27.

7. Villanueva MM. Experiencia de la prueba de NAT en el banco de sangre del Instituto Nacional de Cancerología, México, D.F.. Rev Mex Med Transfus. 2009; 2 (Suppl: 1): 69-71.

8. Camacho-Rodríguez B, NAT en Banco de Sangre ¿Una necesidad o un sobrecosto? IDCBIS, biotecnología e innovación en Salud Bogotá C [internet] 2018. pp. 2-66. Disponible en: https://www.ins.gov.co/Direcciones/RedesSaludPublica/DonacionSangre/Publicaciones/NAT%20en%20Banco%20de%20Sangre%20costo%20o%20sobrecosto%20Dr%20B%20Camacho.pdf

9. Vermeulen M, van Drimmelen H, Coleman C, Mitchel J, Reddy R, Lelie N. A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. Transfusion. 2014; 54 (10): 2496-2504.

10. Sánchez Frenes P, Sánchez Bouza MJ, Hernández Malpi S. Las enfermedades infecciosas y la transfusión de sangre. Rev Latinoamer Patol Clin. 2012; 59 (4): 186-193.

11. Novelo GB, Benítez AG. Reflexiones sobre la seguridad sanguínea en México. Rev Mex Med Transfus. 2014; 7 (1): 45-50.